Registry for people with atypical hemolytic uremic syndrome
Part of Blood & lymphatic, Kidney & urinary, Women’s health & pregnancy clinical trials.
This is a registry that collects information from people diagnosed with atypical hemolytic uremic syndrome (aHUS). It helps researchers better understand the condition across different genetic causes and treatment needs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of aHUS (at any age, including children).
- It can be with or without a known complement gene change (or related blood antibodies).
- You (or your parent/legal guardian for a child) must be able and willing to sign consent forms.
- If you are a minor, you must be willing to give assent (agreement) when required.
- If a test is done, your ADAMTS13 result must be more than 5%.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how rare gene mutations may explain atypical HUS (aHUS) and how that could guide more personalized treatment. It mainly involves people who have had aHUS affecting blood counts and kidneys.
This trial tests the drug ravulizumab for people with aHUS (a rare blood and kidney condition). It aims to see if the drug can help improve blood counts and kidney function.
This study creates a registry to collect health information from people with rare kidney diseases. It aims to improve understanding and future treatments by tracking patient experiences.
This trial tests a new medicine for people with a rare blood disorder called atypical hemolytic uremic syndrome (aHUS) that is still active despite other treatments. The drug aims to stop the ongoing damage to blood cells and kidneys.
This study looks at how common hemolytic uremic syndrome (HUS) is in children. HUS is a rare condition that affects the blood and kidneys. The study helps doctors understand and identify this condition better in young patients.
This study enrolls people with hidradenitis suppurativa (HS) to better understand the condition over time and store optional health information and samples. Being in the registry may help researchers learn about patterns in HS and support future research.
Hear when a new Atypical Hemolytic Uremic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.